Verzenio™

Drug - Verzenio™ (abemacicib) [Eli Lilly and Company]

June 2018

Therapeutic area - Oral Oncology

Initial approval criteria

• Patient must be at least 18 years old AND
• Patient has a diagnosis of advanced or metastatic breast cancer that is 
  • hormone receptor (HR)-positive AND
  • human epidermal growth factor receptor 2 (HER2)-negative AND
• Verzenio is prescribed for use in combination with fulvestrant for patient with disease progression following endocrine therapy OR
• Vernezio is prescribed as monotherapy for patient with disease progression following endocrine therapy and prior chemotherapy
• Initial approval will be for 6 months

Renewal criteria

• Patient continues to meet initial review criteria AND
• Tumor response with stabilization of disease or decrease in size of tumor or tumor spread AND
• Absence of unacceptable toxicity (e.g., increased ALT/AST)
• Renewal approval will be for 6 months

Quantity limits

56 tablets (4 blister packs) per 28 days

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411